Nuwellis (NUWE) Registration filing summary

Company overview and business model

• Commercial-stage medical technology company focused on ultrafiltration therapy for fluid overload patients, primarily through the Aquadex SmartFlow system for adults and children unresponsive to diuretics.

• Incorporated in Delaware, with principal offices in Minnesota; began operations in 1999 and restructured in 2020.

Financial performance and metrics

• Identified as a smaller reporting company with market value of public float under $700 million and annual revenue below $100 million.

• Has incurred operating losses since inception and expects continued losses in the near term; funded primarily by equity financings.

• Gross proceeds from the August 2026 private placement were approximately $3.4 million before fees and expenses.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; will receive up to $3.6 million if all warrants are exercised for cash.

• Proceeds from warrant exercises intended for working capital and general corporate purposes.